



October 2, 2020

Web Announcement 2318

Prescription Drug Coverage for Medication Assisted Treatment (MAT) Update

Effective October 1, 2020, the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act requires state Medicaid entities to cover all Food and Drug Administration (FDA)-approved prescription drugs used for Medication Assisted Treatment (MAT) for a five-year period (October 2020 through September 2025).

The DHCFP confirms that Nevada Medicaid, Fee-for-Service, covers FDA-approved medications used for indications for MAT to treat Opioid Use Disorder (OUD).

The President has signed H.R. 8337, the Continuing Appropriations Act, 2021 and Other Extensions Act. This new law makes statutory change to Section 1905(a)(29) and 1905(ee) of the Act, and now clarifies that MAT drugs when used for OUD as described under the mandatory benefit are defined as prescribed drugs and covered outpatient drugs subject to section 1927 of the Act requirements.

These amendments to the Act ensure the state's ability to seek drug manufacturer rebates and apply drug utilization management.